AVO — Advanced Oncotherapy Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | 49.81 | 77.45 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system integrates a series of modular linear accelerators. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva and Switzerland. The Company’s verification and validation site is located in Daresbury, United Kingdom.
Directors
- Michael Sinclair CHM (77)
- Nicolas Serandour CEO
- Ed Lee
- Geraldine Poindron
- Berengere Pons - Chabord
- Louise Harley-Smeur
- Graham Pughe SVP
- Steve Myers
- Bridget Biggar
- Michel Baelen
- Jonathan Farr
- Manuel Galas
- Moataz Karmalawy
- Julian Tokuta
- Michael Bradfield (63)
- Nick Plowman
- Enrico Vanni (69)
- Hans von Celsing
- Ren Zhang (54)
- Lori Cross (60)
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- September 15th, 2005
- Public Since
- August 4th, 2006
- No. of Employees
- 139
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 349,834,730
- Address
- Third Fl, 4 Tenterden Street, LONDON, W1S 1TE
- Web
- https://www.avoplc.com/
- Phone
- +44 2036178728
- Auditors
- RPG Crouch Chapman LLP
Latest News for AVO
Upcoming events for AVO
Half Year 2021 Advanced Oncotherapy PLC Earnings Release
Similar to AVO
GOOCH AND HOUSEGO ORD
London Stock Exchange
IMAGE SCAN HOLDINGS ORD
London Stock Exchange
MAXCYTE ORD
London Stock Exchange
MAXCYTE ORD
London Stock Exchange
MYHEALTHCHECKED ORD
London Stock Exchange
FAQ
As of Today at 13:35 UTC, shares in Advanced Oncotherapy are trading at 40.00p. This share price information is delayed by 15 minutes.
Shares in Advanced Oncotherapy last closed at 40.00p and the price had moved by +29.03% over the past 365 days. In terms of relative price strength the Advanced Oncotherapy share price has outperformed the FTSE All Share Index by +5.46% over the past year.
The overall consensus recommendation for Advanced Oncotherapy is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Advanced Oncotherapy does not currently pay a dividend.
Advanced Oncotherapy does not currently pay a dividend.
Advanced Oncotherapy does not currently pay a dividend.
To buy shares in Advanced Oncotherapy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 40.00p, shares in Advanced Oncotherapy had a market capitalisation of £1.40m.
Here are the trading details for Advanced Oncotherapy:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AVO
Based on an overall assessment of its quality, value and momentum Advanced Oncotherapy is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Advanced Oncotherapy is 117.50p. That is 193.75% above the last closing price of 40.00p.
Analysts covering Advanced Oncotherapy currently have a consensus Earnings Per Share (EPS) forecast of -£0.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanced Oncotherapy. Over the past six months, its share price has underperformed the FTSE All Share Index by -13.37%.
As of the last closing price of 40.00p, shares in Advanced Oncotherapy were trading +8.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Advanced Oncotherapy.
Advanced Oncotherapy's management team is headed by:
- Michael Sinclair - CHM
- Nicolas Serandour - CEO
- Ed Lee -
- Geraldine Poindron -
- Berengere Pons - Chabord -
- Louise Harley-Smeur -
- Graham Pughe - SVP
- Steve Myers -
- Bridget Biggar -
- Michel Baelen -
- Jonathan Farr -
- Manuel Galas -
- Moataz Karmalawy -
- Julian Tokuta -
- Michael Bradfield -
- Nick Plowman -
- Enrico Vanni -
- Hans von Celsing -
- Ren Zhang -
- Lori Cross -
We do not have data on Advanced Oncotherapy's shareholders